… for his abstract entitled: AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD DATA … Olga Molostova (Russian Federation) - OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING …

… industry, and the reasons for delays in the production of CAR T-cell therapies. The first talk is by Jordi Llinares Garcia … requirements, and also inspired ways to deal with CAR-T cell programmes in terms of centre qualifications and …

… after patients receiving Immune effector cells such as CAR-T therapy, anywhere in the patient pathway. The forum can be …

… transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: … the EBMT Jakob R. Passweg et al  Manufacturing of primary CAR-NK cells in an automated system for the treatment of …

… panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma Leo Rasche et al Impact of … on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the …

… sclerosis. Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been …

… OF CD19 IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CAR-T THERAPY Read the interview JON J. VAN ROOD AWARD  to Janaki … TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome …

… Mortalité non liée à la rechute après thérapie par cellules CAR-T …

… cell transplantation. In the last decade, targeted and T cell engaging therapies literally revolutionised the … allogeneic haematopoietic cell transplantation as well as CAR-T cell therapy applied to all types of lymphoma. We use … B cell non Hodgkin lymphomas , we analysed the outcome of CAR-T cell therapy in different settings such as primary and …

… sclerosis (SSc). Recently, novel cellular therapies (i.e. CAR-T cells, mesenchymal cells) have been successfully adopted in …